MARK1

Across TCGA pan-cancer cohorts, MARK1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MARK1 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MARK1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MARK1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and UCEC are the cancer types where MARK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	1.000	0.343	.006	19	view →
GBM	DFS	Quartile	All	0.909	0.626	<.001	18	view →
UCEC	DFS	Tertile	All	0.951	0.738	.009	12	view →
LSCC	DFS	Quartile	III,IV	1.000	0.333	.005	11	view →
HNSC	DFS	Tertile	II,III,IV	0.898	0.689	.017	3	view →
PDAC	OS	Tertile	II,III,IV	0.377	0.676	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MARK1–CCRCC (OS)

Open the CCRCC breakdown →